Retatrutide (GLP-1/GIP/Glucagon): 24mg

Description

Glp-3 class peptides are triple receptor agonists targeting glp-1, gip, and glucagon receptors simultaneously. adding glucagon receptor activation to the dual glp-1/gip mechanism introduces a third lever: glucagon signaling increases energy expenditure and hepatic fat metabolism, which further amplifies the fat-reduction signal beyond what dual agonists achieve. the three receptor pathways work synergistically across the brain, liver, pancreas, and adipose tissue. phase 2 clinical research on triple agonists showed mean body weight reduction of 24.2% at 48 weeks, with participants still losing weight at study end — indicating a plateau had not yet been reached. phase 3 data has since reported up to 28.7% weight loss. the glucagon component also increases energy expenditure, which researchers propose may explain the energy and cognitive benefits often reported alongside weight reduction. gastrointestinal tolerability is generally comparable to dual agonists. for research and educational purposes only.

Specifications

Dose Calculator